HBeAg-positive CHB patients with indeterminate phase associated with a high risk of significant fibrosis.

ABSTRACT:

Background

The risk of liver fibrosis in HBeAg-positive chronic hepatitis B (CHB) patients with indeterminate phase is not well characterized. We aimed to compare the presence of liver fibrosis in HBeAg-positive CHB patients between indeterminate phase and immune-tolerant phase.

Methods

This multi-center, retrospective cohort study included 719 treatment-naïve HBeAg-positive CHB patients with normal alanine aminotransferase (ALT). Patients with HBV DNA > 10⁶ IU/mL were categorized into immune-tolerant phase, whereas those with HBV DNA ≤ 10⁶ IU/mL were classified into indeterminate phase. Significant liver fibrosis and cirrhosis were determined by APRI, FIB-4, transient elastography, or liver biopsy.

Results

The median age of patients was 33.0 yea

SUBMITTER: Li Y 

PROVIDER: S-EPMC11562367 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature